Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

25.58 -0.09 (-0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 412,708
Open 25.72
Bid (Size) 25.07 (2)
Ask (Size) 26.23 (1)
Prev. Close 25.67
Today's Range 25.53 - 25.77
52wk Range 25.38 - 42.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire

Performance

YTD
-20.34%
-20.34%
1 Month
-8.68%
-8.68%
3 Month
-16.49%
-16.49%
6 Month
-19.46%
-19.46%
1 Year
-31.90%
-31.90%

More News

Read More
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
Via Chartmill
10 Analysts Assess Genmab: What You Need To Know
Via Benzinga
What 9 Analyst Ratings Have To Say About Genmab
Via Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
7 Stocks That Could Safely 10X by 2030
Via InvestorPlace
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Decoding 9 Analyst Evaluations For Genmab
Via Benzinga
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
NASDAQ:GMAB is not too expensive for the growth it is showing.
Via Chartmill
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.